SELECTIVE OX1R ANTAGONIST IN NICOTINE DEPENDENCE INDUCED WITHDRAWAL SYNDROME IN MICE

The present invention relates to the field of pharmaceuticals. 5 Specifically, the present invention relates to a compound that attenuates nicotine dependence induced withdrawal syndrome. The present invention further relates to a compound that is for the treatment and management of nicotine addiction, wherein the compound is a selective Oxerin receptor antagonist.

Inventors

THAKUR GURJEET SINGH, AMARJOT KAUR GREWAL, SONIA DHIMAN

Patent File Number - 202011053497         Patent File Date - 09/12/2020